tbuckley/cabot-search huggingface dataset:
Psychiatry in Spain: past and present
Authors: J Chatel, B Joe
Journal: American Journal of Psychiatry (1975)

The authors discuss the contributions and history of psychiatry in Spain on the basis of extensive literature review and on-site observations. The history of Spanish psychiatry is a rich one, including pioneering efforts in the establishment of mental institutions and a strong traditional alliance between psychiatry and literature. However, the authors note that Spanish psychiatrists today are less innovative than their counterparts in other countries. They emphasize the historical and cultural context of the discipline, with illustrations of the importance of the church, attitudes toward the family, and other sociocultural factors.
Impaired Precursor B-Cell Maturation/Production In The Bone Marrow: Association With Molecular and Immunophenotypic Markers Of Myeloid Dysplasia In Suspected Low-Grade MDS
Authors: Charles Repetti, Hsueh-Hua Chen, Yongbao Wang, Vanessa A Jones, Albert K Ho, Qiulu Pan, Ila Bansal, Dan Jones
Journal: Blood (2013)
The Effects of Caffeine and Theophylline on the Triple Adenosine Triphosphatase Enzyme Activities of Spermatozoa from Males with Oligoasthenospermia
Authors: M. Karacagil, A. Ìmamoğlu, H. Paşaoğlu, Ì. Gülmez, A. Tatlışen
Journal: European Urology (1990)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Authors: Gordon Cook, A John Ashcroft, David A Cairns, Cathy D Williams, Julia M Brown, Jamie D Cavenagh, John A Snowden, Christopher Parrish, Kwee Yong, Jim Cavet, Hannah Hunter, Jenny M Bird, Guy Pratt, Sally Chown, Ernest Heartin, Sheila O'Connor, Mark T Drayson, Anna Hockaday, Treen C M Morris
Journal: The Lancet Haematology (2016)
Embracing the ethically complicated patient
Authors: Daniel Sokol
Journal: BMJ (2016)

Ethical challenges provide opportunities to improve patient care



All clinicians are familiar with the medically complicated patient. Those patients have, for example, overlapping illnesses, complex manifestations of symptoms, or uncommon reactions to treatment. They fill the pages of medical journals as case reports. They are the subject of grand rounds and departmental meetings.

Less celebrated is the ethically complicated patient. These are patient whose circumstances raise perplexing ethical questions for the healthcare team, and the care of such patients was the theme of this year’s International Conference on Clinical Ethics Consultation, in Washington, DC.

The conference was an ethicist’s dream but less so for a clinician, with case after case of conflicting values; tensions between patients, relatives, and medical teams; offensive, abusive, and …
Glitazone in Diabetes
Authors: Christine M. Heckemeyer, Catarina I. Kiefe
Journal: Diabetes Care (2005)

In its evidence-based guidelines for type 2 diabetes (1), the Veterans Health Administration (VHA) recommends a second-generation sulfonylurea or metformin as first-line drug therapy. Metformin or sulfonylurea is added to the first agent if HbA1c (A1C) control is not satisfactory. Because of their modest effect on A1C, unknown long-term safety, and high cost, the VHA recommends reserving thiazolidinediones (glitazones) for selected patients. We compared community versus Veterans Affairs (VA) primary care providers regarding initiation of glitazone therapy and presence of contraindications in veterans, who frequently obtain care both within and outside the VHA.

Glitazone prescription at the Birmingham VA Medical Center (BVAMC) required …
Biosimilars: The US Regulatory Framework
Authors: Leah A. Christl, Janet Woodcock, Steven Kozlowski
Journal: Annual Review of Medicine (2016)

With the passage of the Biologics Price Competition and Innovation Act of 2009, the US Food and Drug Administration established an abbreviated pathway for developing and licensing biosimilar and interchangeable biological products. The regulatory framework and the technical requirements of the US biosimilars program involve a stepwise approach that relies heavily on analytical methods to demonstrate through a "totality of the evidence" that a proposed product is biosimilar to its reference product. By integrating analytical, pharmacological, and clinical data, each of which has limitations, a high level of confidence can be reached regarding clinical performance. Although questions and concerns about the biosimilars pathway remain and may slow uptake, a robust scientific program has been put in place. With three biosimilars already licensed and numerous development programs under way, clinicians can expect to see many new biosimilars come onto the US market in the coming decade. [Note added in proof: Since the writing of this article, a fourth biosimilar has been approved.].
Cardiac Protection in HER2-Targeted Treatment
Authors: Ana Barac, Sandra M. Swain
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
Authors: Daniel E Singer, Robert A Hughes, Daryl R Gress, Mary A Sheehan, Lynn B Oertel, Sue Ward Maraventano, Dyan Ryan Blewett, Bernard Rosner, J Philip Kistler
Journal: New England Journal of Medicine (1990)

Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke.
Cancer in Indigenous Populations and Remote Areas in Brazil: Experience of the Federal University of Sao Paulo.
Authors: Pedro Nazareth Aguiar, Gustavo Trautman Stock, Barbara Gutierres Aguiar, Hakaru Tadokoro, Gilberto Lopes, Douglas Antonio Rodrigues
Journal: Journal of Clinical Oncology (2015)

e17607 Background: Brazil has a significant number of Indigenous communities that are undergoing an epidemiological transition, with increasing incidence of chronic diseases. According to scarce publications, they have a lower cancer incidence than that of the general population, but they have worse outcomes. We aimed to evaluate the most prevalent cancers, risk factors and patients’ access to health services, as well as the efficacy and safety of treatments in Indigenous patients treated at our institution. Methods: We examined medical records from adult patients of different regions of the country who were diagnosed with solid cancers and followed at the Federal University of Sao Paulo Indigenous patient clinic between 2005 and 2014. Individual features and time to access to health services and treatment were analyzed by descriptive statistics; PFS and OS were evaluated by the Kaplan-Meier method; prognostic factors were assessed with Cox regression. Results: 48 pts were included from 19 different ethnic groups; mean age was 54.8 yrs. 56.3% were female. Cervix and prostate cancer were the most frequent tumors (27% and 16.7%, respectively). Mean time between symptoms and diagnosis was 8.8 months (Range 0.7 - 42.3); and between diagnosis and treatment was 3.6 months; 68.7% received treatment. The median PFS was 30.1 months, and the median OS was 81.4 months. Comparing groups that refused vs those that received treatment, the median OS was 5.0 vs 81.4 months (HR 2.71; 95% CI 0.85 - 8.63). Comparing patients with higher than average time between diagnosis and treatment with the lower than average time group, the median OS was 81.4 months vs NR (HR 1.19; 95% CI 0.85 - 4.08). 31.4% of patients were diagnosed at stage IV and it was a prognostic factor (HR 2.48; 95% CI 1.45 – 4.21). 14 pts underwent chemotherapy, 13 were evaluated for response: 30,8% had a CR/PR, 46.2% had SD and 23.1% progressed at 1st evaluation. Neutropenia G3-4 was seen in 28.6% of treated pts. Conclusions: Despite considerable progress in healthcare policies for Indigenous population in Brazil, there is still much to do to decrease disparities in access to cancer diagnosis and treatment. Further research on this subject is clearly warranted to inform public policies
Personal views: Do we hear our patients? And would a patient's page help?
Authors: Jacqueline S Maxmin
Journal: BMJ (2002)

Today I spoke at a medical education meeting about a communication skills course I have been piloting for our senior house officers. Attendance has been patchy and poor. I wondered if the consultants were really supportive about releasing them from duties to attend the course. I tried to explain the importance of integrating both informative and receptive behaviours in the medical interview. Everybody knows that we need to give information accurately in ways that patients can understand. But how can you explain succinctly the importance of the receptive behaviours—that is, understanding what the patient and relatives are really concerned about . . .
The optimization and validation of the Biotyper MALDI-TOF MS database for the identification of Gram-positive anaerobic cocci
Authors: A.C.M. Veloo, E.D. de Vries, H. Jean-Pierre, U.S. Justesen, T. Morris, E. Urban, I. Wybo, A.J. van Winkelhoff, T. Morris, H. Shah, H. Jean-Pierre, U.S. Justesen, E. Nagy, E. Urban, M. Kostrzewa, A. Veloo, A.J. van Winkelhoff, A.W. Friedrich
Journal: Clinical Microbiology and Infection (2016)
Three vole species and one (?) novel arvicolid hantavirus pathogen: Tula virus revisited
Authors: Jan Clement, Marc Van Ranst
Journal: Eurosurveillance (2016)

Preview this article: Three vole species and one (?) novel arvicolid hantavirus pathogen: Tula virus revisited, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/2/eurosurv-21-30108-6-1.gif
Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups
Authors: Thomas Buchner, Wolfgang E. Berdel, Utz Krug, Claudia Haferlach, Susanne Schnittger, Matthias Stelljes, Gerda Silling, Peter Staib, Andreas Grueneisen, Albrecht Reichle, Leopold Balleisen, Hartmut Eimermacher, Aristoteles Giagounidis, Herbert Rasche, Eva Lengfelder, Cristina Sauerland, Achim Heinecke, Bernhard Josef Woermann, Wolfgang Hiddemann
Journal: Blood (2012)
THE CASE OF THE DISAPPEARING BONES
Authors: F A KINGERY
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression of P4H9-detecting molecule on spindle-shaped fibroblasts to indicate malignant phenotype of colorectal cancer.
Authors: Shozo Yokoyama, Junji Ieda, Naoyuki Yamamoto, Yasuyuki Mitani, Katsunari Takifuji, Tsukasa Hotta, Kenji Matsuda, Takashi Watanabe, Hiromitsu Iwamoto, Masaaki Deguchi, Hiroki Yamaue
Journal: Journal of Clinical Oncology (2016)

539 Background: Cancer cells and fibroblasts are coordinated for cancer progression. Our previous study has shown that P4H9, produced by epitope for b2 integrin, detected a molecule on fibroblasts in mammary fat pad mouse model in response to Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) expressing cancer cells. P4H9 detecting molecule (PDM) expression appeared to be associated with myofibroblast differentiation. The aim of the present study is to investigate whether PDM express on fibroblast and cancer cells in clinical tissue samples, and whether PDM expressing cells in colorectal cancer tissue are correlated with clinicopathological features of patients with colorectal cancer. Methods: Immunohistochemistry were conducted with P4H9 on clinical tissue samples from 156 patients with colorectal cancer. The risk factors for metastases and survival were calculated for clinical implication of PDM expressing spindle shaped fibroblasts. Immunofluorescence with P4H9 were performed on CCD-18Co fibroblasts and colorectal cancer cell lines, HT29 and HCT116. Results: Multivariate analysis showed that PDM expressing spindle shaped fibroblasts was an independent risk factor for lymph node metastasis, hematogenous metastasis, and short survival. Kaplan-Meier survival curve presented that PDM expressing spindle shaped fibroblasts was associated with shorter survival time (p&lt; 0.0001). PDM expressing spindle shaped fibroblasts is associated with metastasis and shorter survival of the patients with colorectal cancer. Immunofluorescence showed that PDM expressed on CCD-18Co fibroblasts and colorectal cancer cell lines, HCT116 with fibroblast like morphology. Conclusions: PDM expressing spindle shaped fibroblasts may play a role to bring out malignant phenotype of colorectal cancer. PDM may be a new biomarker and a novel therapeutic target for patients with colorectal cancer.
The Overall Incidence and Pattern of Chemotherapy–Induced Nausea and Vomiting (Cinv) in Carboplatin is Similar to Those of Cisplatin and Should Be Considered a High Risk for Cinv
Authors: K. Tamura, K. Aiba, T. Saeki, M. Shimokawa, K. Hirata, Y. Maehara, M. Kitajima
Journal: Annals of Oncology (2014)
Obesity and Multiple Sclerosis: A Mendelian Randomization Study
Authors: Lauren E. Mokry, Stephanie Ross, Nicholas J. Timpson, Stephen Sawcer, George Davey Smith, J. Brent Richards
Journal: PLoS Medicine (2016)

Background Observational studies have reported an association between obesity, as measured by elevated body mass index (BMI), in early adulthood and risk of multiple sclerosis (MS). However, bias potentially introduced by confounding and reverse causation may have influenced these findings. Therefore, we elected to perform Mendelian randomization (MR) analyses to evaluate whether genetically increased BMI is associated with an increased risk of MS. Methods and Findings Employing a two-sample MR approach, we used summary statistics from the Genetic Investigation of Anthropometric Traits (GIANT) consortium and the International MS Genetics Consortium (IMSGC), the largest genome-wide association studies for BMI and MS, respectively (GIANT: n = 322,105; IMSGC: n = 14,498 cases and 24,091 controls). Seventy single nucleotide polymorphisms (SNPs) were genome-wide significant (p < 5 x 10−8) for BMI in GIANT (n = 322,105) and were investigated for their association with MS risk in the IMSGC. The effect of each SNP on MS was weighted by its effect on BMI, and estimates were pooled to provide a summary measure for the effect of increased BMI upon risk of MS. Our results suggest that increased BMI influences MS susceptibility, where a 1 standard deviation increase in genetically determined BMI (kg/m2) increased odds of MS by 41% (odds ratio [OR]: 1.41, 95% CI 1.20–1.66, p = 2.7 x 10−5, I2 = 0%, 95% CI 0–29). Sensitivity analyses, including MR-Egger regression, and the weighted median approach provided no evidence of pleiotropic effects. The main study limitations are that, while these sensitivity analyses reduce the possibility that pleiotropy influenced our results, residual pleiotropy is difficult to exclude entirely. Conclusion Genetically elevated BMI is associated with risk of MS, providing evidence for a causal role for obesity in MS etiology. While obesity has been associated with many late-life outcomes, these findings suggest an important consequence of childhood and/or early adulthood obesity.
PD-012 Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)
Authors: E. Van Cutsem, F. Ciardiello, M. Ychou, J.-F. Seitz, R. Hofheinz, Y. Arriaga, R. Garcia-Carbonero, A. Grothey, A. Miriyala, J. Kalmus, C. Kappeler, A. Falcone, A. Zaniboni
Journal: Annals of Oncology (2016)
Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors
Authors: Fang Li, Xinjian Liu, John H. Sampson, Darell D. Bigner, Chuan-Yuan Li
Journal: Cancer Research (2016)

Abstract Cancer stem-like cells (CSC) are thought to drive brain cancer, but their cellular and molecular origins remain uncertain. Here, we report the successful generation of induced CSC (iCSC) from primary human astrocytes through the expression of defined genetic factors. Combined transduction of four factors, Myc, Oct-4, p53DD, and Ras, induced efficient transformation of primary human astrocytes into malignant cells with powerful tumor-initiating capabilities. Notably, transplantation of 100 transduced cells into nude mice was sufficient for tumor formation. The cells showed unlimited self-renewal ability with robust telomerase activities. In addition, they expressed typical glioma stem-like cell markers, such as CD133, CD15, and CD90. Moreover, these cells could form spheres in culture and differentiate into neuron-like, astrocyte-like, and oligodendrocyte-like cells. Finally, they also displayed resistance to the widely used brain cancer drug temozolomide. These iCSCs could provide important tools for studies of glioma biology and therapeutics development. Cancer Res; 76(17); 5143–50. ©2016 AACR.
Metabolism of &lt;sc&gt;l&lt;/sc&gt;-Histidine-2-C&lt;sup&gt;14&lt;/sup&gt; in the Normal and the Hepatoma-bearing Rat
Authors: James C. Reid, Martha O. Landefeld, Jane L. Simpson
Journal: JNCI Journal of the National Cancer Institute (1952)

Metabolism of l-Histidine-2-C14 in the Normal and the Hepatoma-bearing Rat Get access James C. Reid, James C. Reid National Cancer Institute, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Martha O. Landefeld, Martha O. Landefeld National Cancer Institute, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Jane L. Simpson Jane L. Simpson National Cancer Institute, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 4, February 1952, Pages 929–936, https://doi.org/10.1093/jnci/12.4.929 Published: 01 February 1952 Article history Received: 26 November 1951 Published: 01 February 1952
P-145 Metastases resection following FOLFIRI-aflibercept in refractory patients to first-line chemotherapy: safety and efficacy analysis
Authors: A. Muñoz, A. Ruiz Casado, C. Pericay, P. Ibeas Millan, R. Grandez Ladrón de Guevara, E. Díaz Peña, M. Lopez Muñoz Ana, I. González Cebrián, A. Moreno Santos Ma, I. Juez Martel, S. Encinas García, J. Alcaide García, I. Machengs Bruquetas, S. García Adrián, M. Lobo de Mena, O. Higuera, I. Ghanem, P. García Alfonso, N. Rodriguez
Journal: Annals of Oncology (2016)
Erratum: Corrigendum: The transcriptional regulator Aire coopts the repressive ATF7ip-MBD1 complex for the induction of immunotolerance
Authors: Michael Waterfield, Imran S Khan, Jessica T Cortez, Una Fan, Todd Metzger, Alexandra Greer, Kayla Fasano, Marc Martinez-Llordella, Joshua L Pollack, David J Erle, Maureen Su, Mark S Anderson
Journal: Nature Immunology (2014)
The Kaiser Permanente Breast Cancer Survivorship National Clinical Algorithm: Regional variation in implementation processes/strategies within an integrated health care system.
Authors: Michele Lagana, Erin Elizabeth Hahn, Joanne E. Schottinger, Susan E Kutner, Mark B Littlewood
Journal: Journal of Clinical Oncology (2016)

104 Background: Kaiser Permanente (KP) is an integrated healthcare system providing comprehensive services to over 10 million members. The KP Interregional Breast Care Leaders, a multidisciplinary clinician group, developed a comprehensive evidence/consensus-based algorithm for breast cancer survivors, the KP Breast Cancer Survivorship National Clinical Algorithm (BCSNCA). The BCSNCA is intended to reduce variation in medical and psychosocial surveillance and improve outcomes by providing guidance to locally implemented survivorship programs, ie, recommendations for surveillance, late effects management, and risk reduction. As a quality improvement project, we evaluated regional/ facility level implementation. Methods: Qualitative data on BCSNCA implementation was collected from key informant interviews with oncology providers for 20 sites in 6 regions: Georgia, Colorado, Hawaii, Southern (KPSC) and Northern California (KPNC), and Mid-Atlantic, and by attending BCSNCA meetings. Implementation activities were recorded, categorized, and compared to BCSNCA. Results: Facilities in 3 regions implemented discrete BCSNCA components: Northwest and Georgia facilities implemented dedicated survivorship clinics; a KPSC facility piloted a nurse navigator standardized psychosocial assessment; KPNC implemented local guidelines, similar to the BCSNCA. One region has not implemented; Georgia implemented all BCSNCA components. There is variation within each region. Implementation drivers include available resources, competing QI priorities/leadership preferences, and adaptability of extant programs. Conclusions: We found variation between and within regions. The BCSNCA content accommodates variation in implementation, guided by a complex set of factors, including resource availability, leadership preferences, and local organizational goals. Even in integrated systems, the need for locally driven guideline adaptation is critical. Next step: assessment of BCSNCA components on patient-level outcomes.
Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases
Authors: Francesca R. Mauro, Robert Foa, Diana Giannarelli, Iole Cordone, Sabrina Crescenzi, Edoardo Pescarmona, Roberta Sala, Raffaella Cerretti, Franco Mandelli
Journal: Blood (1999)
Abstract 13435: Mitochondrial L-arginine Transport Capacity: Implications for Oxidative Stress and the Pathogenesis of Heart Failure
Authors: Kylie M Venardos, David Williams, Zhiyong Yang, Melissa Byrne, David M Kaye
Journal: Circulation (2010)

Accumulating evidence indicates that nitric oxide (NO) is a key regulator of cardiac mitochondrial metabolism and that an isoform of NO synthase exists within mitochondria. To date the biochemical ...